In the near future in an arsenal of doctors there will be a new powerful vaccine from a meningitis. Clinical tests of a preparation have shown its high efficiency.
The information given by pharmaceutical giant Novartis testifies that in organisms of the overwhelming majority of the babies who have received an experimental vaccine from a meningitis In (type caused by a hemophilic rod), the powerful immune answer against illness has been fixed. Charitable association Meningitis UK considers, that these results of clinical researches can lead to creation of a vaccine which will salvage lives of tens thousand children.

The meningitis In is the most widespread form of illness on which share it is necessary to 80 % of all cases. It also the most lethal form of a meningitis as after occurrence of the first symptoms it can kill the person within one-two days. Because of the difficult nature of disease against it all was serious to receive immunity. Now the medicine cannot offer any effective vaccine.

Scientists investigated preparation Multicomponent Meningococcal Serogroup B Vaccine (4CMenB), developed by pharmaceutical company Novartis. During clinical tests a vaccine of a distance to 3 600 babies. The overwhelming majority of examinees after a nyxis have shown the powerful immune answer to three chains of the streptococcuses which are originators of a meningitis of Century
Besides it in organisms of kids the most minimum collateral reaction in comparison with consequences of injections of other vaccines has been fixed. It allows to assume, that 4CMenB can be used everywhere as a vaccine from a meningitis in the first year of a life of the child.